| Similar Articles |
|---|
 |
The Motley Fool
December 2, 2010
Brian Orelli |
A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying.   |
Pharmaceutical Executive
November 1, 2005
Sara Calabro |
Valeant Pharmaceuticals is Soldiering On Valeant Pharmaceuticals' new CEO Tim Tyson restructures the company after legal and financial troubles. |
The Motley Fool
March 30, 2011
Brian Orelli |
Valeant Vultures Will Cephalon manage to rebuff Valeant's advances? |
The Motley Fool
August 10, 2010
Brian Orelli |
When the Disease Matters Most in Drug Approval Glaxo's and Valeant's Potiga will go before an FDA advisory committee tomorrow. |
The Motley Fool
June 14, 2011
Frank Vinluan |
GSK Epilepsy Drug Approved by FDA GlaxoSmithKline and drug partner Valeant Pharmaceuticals have received U.S. Food and Drug Administration approval on a new epilepsy drug, but it must be classified as a controlled substance. |
The Motley Fool
June 21, 2011
Alexander Crawford |
Bullish Biotech: 5 Biotech Firms Making Great Strides These five biotech firms have just received great news. Should they be on your watch list? |
The Motley Fool
June 30, 2006
Stephen D. Simpson |
Johnson & Johnson: This Is More Like It Filling out the drug and device businesses will be good for growth. Investors, take note. |
The Motley Fool
September 30, 2011
Brian Orelli |
When You Need More Than Just a Low-Margin Business Teva Pharmaceuticals, arguably the largest generic-drug maker, can use economies of scale more easily than smaller companies like Watson Pharmaceuticals or Par Pharmaceutical, but it's still pushing further into branded drugs. |
Chemistry World
July 30, 2013
Emma Stoye |
Thousands face job cuts after Valeant's Bausch buyout Canadian pharmaceutical company Valeant plans to lay off up to 2700 staff to help finance its $8.7 billion acquisition of US eye health specialist Bausch & Lomb. |
Pharmaceutical Executive
May 1, 2012 |
Pharm Exec 50: Growth from the Bottom Up More consolidation didn't boost pharmaceutical sales at the top, but a handful of nimble newcomers posted impressive growth on the other end of the curve. |
Chemistry World
July 28, 2014
Andy Extance |
Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover. |
The Motley Fool
June 16, 2011
Brian Orelli |
Are Two FDA Approvals in One Week a Positive Sign? Bristol-Myers Squibb received Food and Drug Administration approval for its kidney transplant drug Nulojix yesterday, marking the second approval this week from the FDA. |
The Motley Fool
July 18, 2007
Brian Orelli |
Metabasis Gets Whacked At some point in the future, Metabasis will likely need to sell more shares or find another partner willing to provide a cash infusion. |
Chemistry World
February 23, 2015
Phillip Broadwith |
Valeant to buy Salix for $14.5bn Serial acquirer Valeant has agreed to buy gastroenterology specialist Salix Pharmaceuticals for $14.5 billion |
The Motley Fool
August 19, 2011
Cindy Johnson |
12 Pharmaceutical Stocks the Insiders Are Buying Folks in the know think these pharmaceutical stocks will rise. Should you join them? |
Chemistry World
September 6, 2012
Andrew Turley |
Valeant buys $2.6bn skincare firm Canadian pharma company Valeant is to buy US firm Medicis in a $2.6 billion deal. Medicis produces prescription dermatology products as well as over the counter products. |
Chemistry World
September 10, 2015
Katrina Megget |
Merger fever sweeps pharma Cheap financing, among other factors, is allowing companies to stock their drug pipelines through acquisitions |
The Motley Fool
April 11, 2011
Jim Mueller |
A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too. |
BusinessWeek
June 16, 2011
Mider & McCracken |
M&A: The Markets Love a Buyer Contrary to conventional wisdom, the announcement of an acquisition is likely to lift the stock price of the company doing the buying. |
The Motley Fool
May 3, 2011
Brian Orelli |
Teva's Branded-Drug Binge For a company that's a generic-drug maker, Teva Pharmaceuticals sure does like its branded drugs. Despite the warts the company is ponying up $6.2 billion to buy Cephalon. |
Chemistry World
January 6, 2015
Sarah Houlton |
Riding new waves Global annual spending on medicines is set to top $1 trillion for the first time in 2014, having ended 2013 just shy of that figure at $989 billion. |
The Motley Fool
August 24, 2010
Travers & Jayson |
Will Valeant Pharmaceuticals Burn You? How well has Valeant Pharmaceuticals International tapped the capital markets? Here's a visual summary of the past few years |
Chemistry World
May 4, 2011
Andrew Turley |
Teva sidelines Valeant with $6.8bn Cephalon bid US drugmaker Cephalon has agreed to a $6.8 billion ( 4.1 billion) takeover bid from Israeli generics manufacturer Teva, which has beaten into second place Canadian pharma company Valeant. |
Chemistry World
March 25, 2015
Phillip Broadwith |
Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals. |
Chemistry World
November 24, 2014
Andy Extance |
Actavis rescues Allergan with $66 billion deal The acrimonious seven-month battle over the future of US biotech Allergan looks to be over, after the Botox-maker accepted a 'white knight' takeover bid from Actavis. |
The Motley Fool
January 30, 2006
Stephen D. Simpson |
Speed the Plough Schering-Plough is still in a precarious position, but it's likely to have above-average growth. It is also one of the few pharmaceuticals whose risk level is actually decreasing. This could be a stock worth owning for some time. |
The Motley Fool
December 31, 2010
Brian Orelli |
How the Other Half of Pharma Lives A dive into spec pharma. |
Chemistry World
April 29, 2014
Phillip Broadwith |
Valeant launches hostile bid for Allergan US drugmaker Valeant has lined up its next takeover target: Botox provider Allergan. Valeant has taken its proposal direct to shareholders, but Allergan has activated a 'poison pill' defense to buy time. |
The Motley Fool
September 23, 2010
Brian Orelli |
Ugly Side Effects Won't Derail This Drug Side effects don't matter much when there are no other treatment options, as in Cushing's disease. |
The Motley Fool
August 17, 2010
Travers & Jayson |
Interested in Cephalon ? Start Here! Every biotech company wants to discover the cure for cancer, Alzheimer's, or Wii knee. Every biotech investor hopes to catch the next Valeant Pharmaceuticals. |
Pharmaceutical Executive
September 1, 2014
Bill Trombetta |
13th Annual Industry Audit After a dip into negative territory in 2012, 2013 delivered a resurgence in sales revenues, but the turnaround only spotlights a larger trend: the growing divide between the big Pharmas and the more nimble players. |
Pharmaceutical Executive
June 9, 2014
Cliff Kalb |
The Urge to Merge Deal making lessons for pharmaceutical companies from history's storyboard. |
Chemistry World
August 26, 2015
Sarah Houlton |
Female sexual desire drug approved Almost five years after Boehringer Ingelheim stopped development on the female hypoactive sexual desire disorder treatment flibanserin, it has been approved by the US Food and Drug Administration. |
The Motley Fool
August 18, 2010
Brian Orelli |
More Pain Ahead for Eli Lilly? An advisory panel meeting tomorrow could further the company's slide. |
